Cargando…

Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis

BACKGROUND: Inclisiran is a novel, cholesterol-lowering therapy, with a long duration of effect, administered every 6 months (subcutaneously by a healthcare professional). In the ORION-10 trial in US patients with atherosclerotic cardiovascular disease (ASCVD) in addition to maximum tolerated statin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Desai, Nihar R., Campbell, Caresse, Electricwala, Batul, Petrou, Margaret, Trueman, David, Woodcock, Fionn, Cristino, Joaquim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468070/ https://www.ncbi.nlm.nih.gov/pubmed/35595929 http://dx.doi.org/10.1007/s40256-022-00534-9

Ejemplares similares

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023)

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
por: Sinning, David, et al.
Publicado: (2020)

Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis
por: Rogula, Sylwester, et al.
Publicado: (2021)

The Achievement of Non-high-density Lipoprotein Cholesterol Target in Patients with Very High Atherosclerotic Cardiovascular Disease Risk Stratified by Triglyceride Levels Despite Statin-controlled Low-density Lipoprotein Cholesterol
por: Al-Sabti, Hilal, et al.
Publicado: (2022)

Inclisiran adjuvant therapy to statins for the use of hypercholesterolemia: a commentary
por: Vohra, Laiba Imran, et al.
Publicado: (2023)

Inclisiran—A Revolutionary Addition to a Cholesterol-Lowering Therapy
por: Dec, Adrianna, et al.
Publicado: (2023)

Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
por: Nishikido, Toshiyuki
Publicado: (2023)

Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease
por: Albosta, Michael S, et al.
Publicado: (2023)

Prognostic effect of high-density lipoprotein cholesterol level in patients with atherosclerotic cardiovascular disease under statin treatment
por: Li, Yi-Heng, et al.
Publicado: (2020)

Inclisiran: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function
por: Di Costanzo, Assunta, et al.
Publicado: (2023)

Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low‐Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients
por: Okerson, Ted, et al.
Publicado: (2017)

Achievement of low-density lipoprotein cholesterol targets in Chinese patients with atherosclerotic cardiovascular disease after receiving statins and ezetimibe
por: Cheng, Yinchu, et al.
Publicado: (2022)

Correction to: Inclisiran: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Of statins and low-density lipoprotein cholesterol, “fats” and fiction
por: Unnikrishnan, Ambika Gopalakrishnan, et al.
Publicado: (2016)

Low‐Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events
por: Willeit, Peter, et al.
Publicado: (2020)

Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
por: Doi, Takahito, et al.
Publicado: (2023)

The N‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions
por: Lehoux, Dario, et al.
Publicado: (2023)

Inclisiran: a novel drug for the treatment of dyslipidemia
por: Nadeem, Abdullah, et al.
Publicado: (2023)

A Statin-Loaded Reconstituted High-Density Lipoprotein Nanoparticle Inhibits Atherosclerotic Plaque Inflammation
por: Duivenvoorden, Raphaël, et al.
Publicado: (2014)

Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
por: Bardolia, Chandni, et al.
Publicado: (2021)

Familial Resemblance in Low‐Density Lipoprotein Cholesterol Response to Statins in the Danish Population
por: Corn, Giulia, et al.
Publicado: (2022)

Low-density lipoprotein cholesterol, statin therapy, and cerebral microbleeds: The CIRCLE study
por: Zhao, Yuqi, et al.
Publicado: (2023)

High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany
por: Makhmudova, U., et al.
Publicado: (2023)

Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia
por: Kosmas, Constantine E., et al.
Publicado: (2018)

Inclisiran: How Widely and When Should We Use It?
por: Pirillo, Angela, et al.
Publicado: (2022)

Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease
por: Patel, Parth N., et al.
Publicado: (2020)

Statin therapy in patients with acute coronary syndrome: low-density lipoprotein cholesterol goal attainment and effect of statin potency
por: Chinwong, Dujrudee, et al.
Publicado: (2015)

Baseline low-density lipoprotein cholesterol predicts the benefit of adding ezetimibe on statin in statin-naïve acute coronary syndrome
por: Im, Jihaeng, et al.
Publicado: (2021)

Low Levels of Low-Density Lipoprotein Cholesterol and Mortality Outcomes in Non-Statin Users
por: Sung, Ki-Chul, et al.
Publicado: (2019)

Low‐density lipoprotein cholesterol lowering in real‐world patients treated with evolocumab
por: Desai, Nihar R., et al.
Publicado: (2021)

High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention
por: Seo, Suk Min, et al.
Publicado: (2011)

New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran
por: Ruscica, Massimiliano, et al.
Publicado: (2021)

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
por: Ray, Kausik K, et al.
Publicado: (2022)

Effectiveness and safety of Inclisiran in hyperlipidemia treatment: An overview of systematic reviews
por: Li, Jiayi, et al.
Publicado: (2023)

High Levels of Remnant Lipoprotein Cholesterol Is a Risk Factor for Large Artery Atherosclerotic Stroke
por: Kim, Jeong-Yeon, et al.
Publicado: (2011)

Optimal Target Level of Low-density Lipoprotein Cholesterol for Vascular Function in Statin Naïve Individuals
por: Matsui, Shogo, et al.
Publicado: (2017)

Low-Density Lipoprotein Cholesterol Level, Statin Use and Myocardial Infarction Risk in Young Adults
por: Jeong, Heekyoung, et al.
Publicado: (2022)

Burden of relapsing-remitting multiple sclerosis on workers in the US: a cross-sectional analysis of survey data
por: Nicholas, Jacqueline A., et al.
Publicado: (2019)

To be Functional, or not to be Low in Cholesterol, that is the Clinical Concern when Evaluating Anti-Atherosclerotic Actions of High-Density Lipoproteins
por: Yoshida, Hiroshi
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uqhnhsklurefejaicak5ahuc9l